Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a fixed-dose herbal combination consisting of peppermint oil (Mentha x piperita L.) and caraway oil (Carum carvi L.), specifically developed by Dr. Willmar Schwabe (often referred to by the code WS 1520). It is primarily indicated for the treatment of functional gastrointestinal disorders, including functional dyspepsia and irritable bowel syndrome (IBS). The mechanism of action is multi-targeted: peppermint oil acts as a local spasmolytic on the smooth muscles of the gastrointestinal tract by blocking voltage-gated calcium channels, while caraway oil exerts carminative effects and acts synergistically to reduce bloating, flatulence, and abdominal pain. The formulation is typically enteric-coated to bypass the stomach and target the intestines, thereby reducing the risk of gastrointestinal reflux or heartburn associated with peppermint oil.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on peppermint oil + caraway oil.